Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382699 | 1.00 | ABCB1 (0.72) | ABCB1ABCG2MAPTBCHECYP2C19 | |
| SCHEMBL25210359 | 0.88 | ABCG2 (0.63) | ABCB1ABCG2MAPTBCHECYP2C19 | |
| SCHEMBL30383512 | 0.88 | ABCG2 (0.63) | ABCB1ABCG2MAPTBCHECYP2C19 | |
| SCHEMBL25197971 | 0.85 | ABCG2 (0.60) | ABCB1ABCG2MAPTBCHECYP2C19 | |
| SCHEMBL25202177 | 0.84 | ABCB1 (0.64) | ABCB1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL25193926 | 0.84 | ABCB1 (0.64) | ABCB1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL25265259 | 0.84 | ABCB1 (1.00) | ABCB1KMT2ALMNA | |
| SCHEMBL25192753 | 0.84 | ABCB1 (1.00) | ABCB1KMT2ALMNA | |
| SCHEMBL25283004 | 0.84 | ABCB1 (0.64) | ABCB1MEN1KMT2ALMNAKCNH2 | |
| SCHEMBL25235490 | 0.84 | ABCB1 (0.64) | ABCB1MEN1KMT2ALMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCB1 1289/4885ABCG2 1606/4885MAPT 3297/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | ABCB1 3877/4885ABCG2 3622/4885MAPT 3512/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCB1 3877/4885ABCG2 3622/4885MAPT 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.